The hepatic clearance and the effects of a new fluorinated macrolide (P-0501A) on the functions of the isolated, perfused rat liver were compared with two known erythromycinsthe base and the estolate -after 7 days of treatment (1.36 mmol/kg po daily). The in vitro metabolism of the antibiotics was induced to different extent but only the base and P-0501A were cleared from the perfusate and the liver faster than in untreated animals. In untreated rats the therapeutically active form of P-0501A was excreted in the bile more than the base and the estolate; after pretreatment, biliary excretion of all erythromycins was nearly double. The content of inactive, complexed cytochrome P.450 was increased only by the base and estolate, with various effects on microsomal activities (some induced, e.g. aminopyrine demethylation, other reduced, e.g. pentobarbital clearance).
The hepatic clearance and the effects of a new fluorinated macrolide (P-0501A) on the functions of the isolated, perfused rat liver were compared with two known erythromycinsthe base and the estolate -after 7 days of treatment (1.36 mmol/kg po daily). The in vitro metabolism of the antibiotics was induced to different extent but only the base and P-0501A were cleared from the perfusate and the liver faster than in untreated animals. In untreated rats the therapeutically active form of P-0501A was excreted in the bile more than the base and the estolate; after pretreatment, biliary excretion of all erythromycins was nearly double. The content of inactive, complexed cytochrome P.450 was increased only by the base and estolate, with various effects on microsomal activities (some induced, e.g. aminopyrine demethylation, other reduced, e.g. pentobarbital clearance).
The clearance and biliary excretion of sulphobromophthalein was not affected by treatment with P-0501A or the base, but was significantly reduced by estolate.
Erythromycin base and estolate are orally active antibiotics which concentrate in the liver where they are partly inactivated by demethylation and partly excreted in an active form in the bile1). Both drugs have major limitations: The base is inactivated by gastric juice and the estolate, though more gastro-resistant, is hepatotoxic in humans2) and in experimental models3-6). Moreover repeated administration of erythromycins to humans7) and rats8-10) induces biosynthesis of microsomal enzymes and promotes formation of metabolites which bind and inactivate cytochrome P-450; hepatic mixed function oxidase activities are variously affected, some being induced but most inhibited2,10). It was found that anew fluorinated macrolide (8S)-8-fluoroerythromycin A (P-0501 A, see Fig. 1 )t11), was more active when given orally12,13) and less toxic in liver cell culture6) than erythromycin base; it does not form inactive cytochrome P-450-metabolite complexes and does not affect the metabolism of other compounds after prolonged treatment10). In order to compare the effects of the new derivative, the base and the estolate on hepatic clearance and liver functions we used perfused livers isolated from animals after 7 days of treatment (1.36 mmol/kg daily).
Materials and Methods

Chemicals
The three macrolides, P-0501A (flurithromycin, see Fig. 1 ), erythromycin base and estolate were kindly supplied by Pierrel S.p.A., Milan, Italy. All other chemicals were analytical grade.
Animals
Male Crl: CD (SD) BR rats (Charles River, Calco, Italy) weighing 160-180 g were fed a standard diet ad lib. (Altromin MT, Rieper, Vandoies, Italy) and housed under controlled conditions (22+0.5°C, 55 % relative humidity, 12/12 light/dark cycle).
Treatments
Rats were given suspensions of the erythromycins in corn oil orally (by gastric tube), 1.36 mmol per kg divided into two daily doses, for 7 consecutive days. Control animals received 8 ml of corn oil/ kg/day. Animals were used as liver donors 24 hours after the last dose.
Liver Perfusion Livers were isolated by the usual surgical technique14) under Na-phenobarbital (50 mg/kg) and chloralose (60 mg/kg) anesthesia; the biliary duct and portal vein were cannulated. The perfusion medium contained one-third homologous difibrinated blood, two-thirds Krebs-Ringer bicarbonate buffer pH 7.4 with 4 % of bovine serum albumin and 0.1 % of glucose.
The drugs, dissolved in dimethyl sulfoxide, were used at the concentration of 68 x 10-6 M (equivalent to 50 ug erythromycin base/ml perfusion medium). The initial volume of medium was proportional to the liver weight, 9 ml/g tissue and flow rate was 1 ml/g liver/minute. Sulfobromophthalein (BSP) was added at a concentration of 1 mg/g liver 10 minutes after perfusion was started. In some experiments pentobarbital was added to the perfusion medium at the concentration of 25 ug/ml in order to measure the influence of the in vivo treatment with erythromycin on the metabolism of this xenobiotic.
Analysis of the Perfusate
The following parameters were studied during 3-hours' perfusion: The concentration of the erythromycins15), BSP16) and pentobarbital17), the activity of glutamic-oxalacetic transaminase (GOT) and urea levels (Boehringer assay kits, Mannheim, West Germany). The perfusion medium and BSP did not interfere with erythromycin determination.
Bile Analysis
The bile flow and the excretion of erythromycins15) and BSP16) were determined. At the end of the perfusion the liver was weighed and one lobe was used to measure ATP18) and erythromycins15). The remaining tissue was homogenized, microsomes were prepared as previously described19) and uncomplexed cytochrome P-45020) was determined. The total amount of cytochrome P-450 was measured by the same procedure"" after first adding 50 µM potassium ferricyanide to another batch of microsomes. N-Demethylation of erythromycin21) and aminopyrine19) were assayed using microsomes treated with 50 uM ferricyanide to break the inactive cytochrome P-450-metabolite complex.
Kinetic and Statistical Calculations
The disappearance of erythromycins, BSP and pentobarbital from the perfusion medium followed first order kinetics:
Ct= C0 -eKt where C0 is the initial concentration of the compounds, K is the first order elimination rate constant and Ct is the concentration at time t. Mean hepatic clearance was calculated from the formula: VOL 
Perfusion of Isolated Liver
The fate of erythromycin base, estolate and P-0501A added to perfused rat liver was followed in perfusion medium, liver tissue and bile after 7-days' treatment with the same drugs (1.36 mmol/kg daily). The clearance of erythromycin base and P-0501A by liver of treated rats was respectively three and two times that in untreated animals ( Table 1 ). The amount of active drug in the liver after 3-hours' perfusion with 50 ug/ml of erythromycin base and P-0501A was considerably lower (11 % the base and 50% P-0501 A), than in untreated animals ( Table 1 ). Biliary excretion of P-0501A in untreated rats was significantly higher than that of the base and estolate; after in vivo treatment excretion of all three erythromycins in bile was about double that in untreated animals ( Table 1) . Pretreatment with erythromycin estolate did not affect its hepatic clearance or the amount of active drug in the liver after perfusion (Table 1) .
Microsomal Metabolism
After pretreatment and 3-hours' perfusion demethylation of the base was highly induced (four times); P-0501A and estolate metabolism was also significantly induced but to a lower extent ( Table 2 ). The demethylation of another substrate, aminopyrine, was induced by treatment with the base and the estolate but not by P-0501A (Table 2) . Correspondingly the total content of cytochrome P-450 was not affected by pretreatment with P-0501A but was significantly raised by the base and estolate; part of it (30% and 55% respectively) was bound in complexes which could be broken in vitro with potassium ferricyanide (Table 2 ). The formation of inactive complexes affected the metabolism of some substrates, e.g.
pentobarbital, whose hepatic clearance was significantly reduced in perfused livers isolated from rats pretreated with the base and estolate (Table 3) , in agreement with in vivo results10).
Effects of Erythromycins on Hepatic Functions
In untreated rats clearance and bile excretion of BSP were affected to different extents by the three erythromycins at the concentration of 50 µg/ml (Table 4) . Both parameters were slightly reduced by the base and P-0501A (about 25%) and much more by the estolate (about 50%). Pretreatment with the base and P-0501A did not affect clearance and biliary excretion of BSP. When 50 ug/ml of these drugs were added to the perfusion medium both parameters were reduced to the same extent (about 30 %, Table 4 ). Clearance and biliary excretion of BSP were significantly reduced by in vivo treatment with the estolate. The presence of this antibiotic in the perfusion medium (50 ug/ml) reduced these parameters by about 70% (Table 4 ). Other parameters of liver function, bile production, urea production, GOT leakage into the perfusion medium and ATP content in the liver were not affected by pretreatment with the antibiotics (data not shown). The rats were treated with one of the erythromycins (E) (1.36 mmol/kg po daily) for 7 days and 24 hours after the last dose the livers were perfused with pentobarbital (25 ug/ml medium). a P<0.05 vs. control, b P<0.01 vs. control.
Discussion
Erythromycin derivatives are widely used for the treatment of various human infections, but some of them may induce hepatotoxicity (estolate)2-6) or interfere with drug metabolism (base, estolate7-16)) More stable, less toxic derivatives have been sought and a new fluorinated erythromycin, P-0501A (see Fig. 1 ), has been found to be more bioavailable when given orally 12,13), less toxic in liver cell culture than the base6) and without influence on the metabolism of other xenobiotics10). As shown in previous communications 12.13) the new derivative was well absorbed and homogeneously distributed in all considered rat organs after oral administration.
Similar distribution characteristics were also found in dogs25). Actually studies on metabolite formation of P-0501A are in progress.
The results of this study show that P-0501A and the base do not interfere with some functions of the perfused liver isolated from rats pretreated with the same drugs for 7 days. BSP removal from the perfusate and its excretion in bile were not affected by the base or P-0501A treatment but they were greatly reduced by the estolate. It has been reported that the physico-chemical characteristics of the estolate, which lowers surface tension more than the base and is more lipophilic than both the base and the new derivative, might affect the membrane interphase, possibly result in modified uptake of other compounds (e.g. BSP)5). The uptake of estolate itself from the liver is also impaired compared with the base and P-0501 A, which are cleared sooner from the perfusate and are left in only small amounts in the liver after 3-hours' perfusion.
Therefore it seems that after in vitro treatment the uptake of these erythromycins from the liver is the result of a compromise between induced metabolism and the condition of the cell membrane. The estolate is also excreted much less in its therapeutically active form in bile compared with the base and P-0501A. After pretreatment excretion of all erythromycins was nearly double than in untreated liver, but the same order was kept: P-0501A> base>> estolate-suggesting marked enterohepatic recycling of the new fluorinated derivative. In agreement with previous in vivo results10) the base and the estolate, but not P-0501A, by inducing the formation of inactive cytochrome P-450 complexes, variously affect mono-oxygenase activities, some being increased (aminopyrine demethylation) and others reduced (pentobarbital clearance).
In conclusion, in perfused liver isolated after 7-days' treatment of rats our observations show that:
1) The new fluorinated derivative does not affect the liver functions, and its clearance from the perfusate and the liver being increased, like the base.
2) Although the metabolism of P-0501A is induced, mono-oxygenase activities are not affected, unlike both the base and estolate.
3) The therapeutically active form of P-0501A is excreted more in bile than the estolate and the base.
